 | Up a level |
Li, Huayi and Peng, Zikun and Zhu, Jianqing and Zhao, Weidong and Huang, Yi and An, Ruifang and Zheng, Hong and Qu, Pengpeng and Wang, Li and Zhou, Qi and Wang, Danbo and Lou, Ge and Wang, Jing and Wang, Ke and Kong, Beihua and Xie, Xing and Yin, Rutie and Low, John and Rozita, Abdul Malik and Sen, Lim Chun and Meng, Yong Chee and Kiong, Kho Swee and Liu, Jihong and Liang, Zhiqing and Lv, Weiguo and Zhu, Yaping and Hu, Weiguo and Sun, Wei and Su, Jingya and Wang, Qiqi and Zang, Rongyu and Ma, Ding and Gao, Qinglei (2024) Exploratory biomarker analysis in the phase III L-MOCA study of olaparib maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer. BMC Medicine, 22 (1). p. 199. ISSN 1741-7015, DOI https://doi.org/10.1186/s12916-024-03409-9.
Gao, Qinglei and Zhu, Jianqing and Zhao, Weidong and Huang, Yi and An, Ruifang and Zheng, Hong and Qu, Pengpeng and Wang, Li and Zhou, Qi and Wang, Danbo and Lou, Ge and Wang, Jing and Wang, Ke and Low, John and Kong, Beihua and Abdul Malik, Rozita and Sen, Lim Chun and Yin, Rutie and Xie, Xing and Liu, Jihong and Sun, Wei and Su, Jingya and Zhang, Chunyi and Zang, Rongyu and Ma, Ding (2022) Olaparib Maintenance Monotherapy in Asian Patients with Platinum-Sensitive Relapsed Ovarian Cancer: Phase III Trial (L-MOCA). Clinical Cancer Research, 28 (11). pp. 2278-2285. ISSN 1078-0432, DOI https://doi.org/10.1158/1078-0432.CCR-21-3023.
